GeoPharma to launch desloratadine tablets
This article was originally published in The Tan Sheet
Executive Summary
GeoPharma can commercially launch a generic version of Schering Corp.'s Clarinex desloratadine tablets (5 mg) beginning July 2012, under a settlement agreement with Schering, Sepracor and the University of Massachusetts. "The new product launch may be a prescription or over-the-counter product depending on its status at the time of launch," Largo, Fla.-based GeoPharma notes in a Jan. 20 announcement. The company will have six months of marketing co-exclusivity to sell the allergy relief product. The settlement resolves all Hatch-Waxman litigation related to the desloratadine tablets triggered when GeoPharma filed paragraph IV certification for the product
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.